Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Maravai LifeSciences Holdings, Inc. (MRVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.99, with a market capitalisation of $996.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.55 to $9.42. This page covers its latest market performance, valuation, price trends and company information.
$996.00M | |
$6.88 | |
$63.55 | |
$1.67 | |
$6.88 | |
11.00 | |
3.48M | |
-- | |
$9.42 | |
$2.55 | |
-- | |
-- |
Maravai LifeSciences Holdings, Inc. (MRVI) is trading at $6.99 in pre-market trading as of 2026-09-16 08:20:00, up 1.54% ($0.11) from the previous close of $6.88
Pre-market trading shows how investors are pricing MRVI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Maravai LifeSciences Holdings, Inc. (MRVI) moved from $7.32 to $6.99, representing a decline of 4.56% ($0.33).
The stock traded between $6.49 and $7.44 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.51 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 64.6%
MRVI is currently trading at $6.99, placing it 64.6% of the way from its 52-week low of $2.55 to its 52-week high of $9.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 415 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Maravai LifeSciences Holdings, Inc. (MRVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.